Antiphospholipid antibodies (aPL) have been associated with various neurological manifestations, but the underly-ing mechanism has not been elucidated. We assessed mice with induced experimental antiphospholipid syndrome (APS) for neurological and behavioral changes. After immuniza-tion with monoclonal human anticardiolipin antibody (H-3), female BALB/c mice developed elevated levels of circulating anti–negatively charged phospholipids (aPL), anti–
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) character...
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous system (...
The clinical associations of antiphospholipid antibodies (aPL) are well recognized but the mechanism...
Antibodies against phospholipids and phospholipid binding proteins (aPL) have been identified as the...
Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory ...
To study whether monoclonal anticardiolipin antibodies (aCL), derived from patients with antiphospho...
Antiphospholipid syndrome (APIS) is characterized by throm-bocytopenia, thromboembolic phenomena, an...
Clinical studies of the association of antiphosphoiipid antibodies (aPL) with thrombosis, fetal deat...
The antiphospholipid antibody syndrome (APS) is characterized by thrombocytopenia, recurrent thrombo...
Antiphospholipid syndrome (APS) is characterized by thromboses and neuropsychiatric manifestations p...
OBJECTIVES: To determine whether active immunisation of mice with pathogenic anticardiolipin antibod...
The antiphospholipid syndrome (APS) defines the clinical association between antiphospholipid antibo...
Objective. Antiphospholipid antibodies (aPL), especially against phosphatidylserine and cardiolipin,...
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous system (...
The clinical features of antiphospholipid (or Hughes’) syndrome (APS) are most commonly seen in indi...
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) character...
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous system (...
The clinical associations of antiphospholipid antibodies (aPL) are well recognized but the mechanism...
Antibodies against phospholipids and phospholipid binding proteins (aPL) have been identified as the...
Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory ...
To study whether monoclonal anticardiolipin antibodies (aCL), derived from patients with antiphospho...
Antiphospholipid syndrome (APIS) is characterized by throm-bocytopenia, thromboembolic phenomena, an...
Clinical studies of the association of antiphosphoiipid antibodies (aPL) with thrombosis, fetal deat...
The antiphospholipid antibody syndrome (APS) is characterized by thrombocytopenia, recurrent thrombo...
Antiphospholipid syndrome (APS) is characterized by thromboses and neuropsychiatric manifestations p...
OBJECTIVES: To determine whether active immunisation of mice with pathogenic anticardiolipin antibod...
The antiphospholipid syndrome (APS) defines the clinical association between antiphospholipid antibo...
Objective. Antiphospholipid antibodies (aPL), especially against phosphatidylserine and cardiolipin,...
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous system (...
The clinical features of antiphospholipid (or Hughes’) syndrome (APS) are most commonly seen in indi...
Antiphospholipid antibodies (aPL) have been most strongly associated with a syndrome (APS) character...
Antiphospholipid syndrome (APS) is a multiorgan disease often affecting the central nervous system (...
The clinical associations of antiphospholipid antibodies (aPL) are well recognized but the mechanism...